{"id":"NCT03622593","sponsor":"Hoffmann-La Roche","briefTitle":"A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema","officialTitle":"A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (RHINE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-09","primaryCompletion":"2020-10-19","completion":"2023-05-31","firstPosted":"2018-08-09","resultsPosted":"2022-03-22","lastUpdate":"2025-07-11"},"enrollment":951,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Macular Edema"],"interventions":[{"type":"DRUG","name":"Aflibercept","otherNames":["Eylea"]},{"type":"DRUG","name":"Faricimab","otherNames":["VABYSMO™","RO6867461","RG7716"]},{"type":"PROCEDURE","name":"Sham Procedure","otherNames":[]}],"arms":[{"label":"A: Faricimab 6 mg Q8W","type":"EXPERIMENTAL"},{"label":"B: Faricimab 6 mg PTI","type":"EXPERIMENTAL"},{"label":"C: Aflibercept 2 mg Q8W","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).","primaryOutcome":{"measure":"Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations","timeFrame":"From Baseline through Week 56","effectByArm":[{"arm":"A: Faricimab 6 mg Q8W","deltaMin":11.8,"sd":null},{"arm":"B: Faricimab 6 mg PTI","deltaMin":10.8,"sd":null},{"arm":"C: Aflibercept 2 mg Q8W","deltaMin":10.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG002","p":"0.1718"},{"comp":"OG001 vs OG002","p":"0.4602"},{"comp":"OG000 vs OG002","p":"0.0361"},{"comp":"OG001 vs OG002","p":"0.4930"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":188,"countries":["United States","Argentina","Australia","Brazil","Canada","China","Czechia","Denmark","France","Germany","Hong Kong","Hungary","Italy","Poland","Portugal","Russia","Singapore","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["38158159","40496217","39580145","37585454","36897413","36246184","35085503"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":97,"n":317},"commonTop":["Cataract","Nasopharyngitis","Conjunctival haemorrhage","Diabetic retinal oedema","Vitreous detachment"]}}